These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9756416)

  • 1. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
    Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
    Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
    Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
    Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
    Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
    Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
    Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
    Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
    Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
    J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
    Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
    Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
    Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
    Sella A; Kilbourn RG; Gray I; Finn L; Zukiwski AA; Ellerhorst J; Amato RJ; Logothetis CJ
    Cancer Biother; 1994; 9(2):103-11. PubMed ID: 7812360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower concentrations of methyl-β-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood.
    Lü HZ; Zhu AY; Chen Y; Tang J; Li BQ
    Hum Immunol; 2011 Jul; 72(7):538-46. PubMed ID: 21540068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.